Search for Clinical Trial Results
Nephrogenic Fibrosing Dermopathy - 15 Studies Found
Status | Study |
Terminated |
Study Name: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) Condition:
|
Completed |
Study Name: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels Condition:
|
Completed |
Study Name: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec Condition: Nephrogenic Systemic Fibrosis Date: 2009-09-21 Interventions: Drug: Imatinib mesylate (Glivec) 400 mg, one tablet daily for 12 or 24 weeks |
Completed |
Study Name: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis Condition: Nephrogenic Systemic Fibrosis Date: 2009-03-17 |
Completed |
Study Name: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis Condition: Nephrogenic Systemic Fibrosis Date: 2008-05-08 Interventions: Drug: Imatinib mesylate 400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants dev |
Suspended |
Study Name: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection Condition:
Date: 2008-12-18 |
Suspended |
Study Name: Nephrogenic Systemic Fibrosis With Gadollinum Condition:
Date: 2009-10-26 Interventions: Drug: gadollinum use of on injection gadollinum Iv for imaging |
Completed |
Study Name: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR Condition: Nephrogenic Systemic Fibrosis Date: 2010-06-01 Interventions: Drug: Ablavar One dose of Ablavar will be administered for use during a contrast MRI examination |
Completed |
Study Name: Primovist / Eovist in Renally Impaired Patients Condition: Contrast Media Date: 2009-05-26 Interventions: Drug: Gadoxetic acid disodium (Primovist, BAY86-4873) Primovist/Eovist in approved indications at approv |
Completed |
Study Name: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist Condition:
Date: 2008-08-20 Interventions: Drug: Gadopentetate dimeglumine (Magnevist, BAY86-4882) Patients will be followed for 2 years after the |